SCHEMBL13178690

SCHEMBL13178690

CCc1cccc(C(CC)CC)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
KCNH2 Q12809 1/20 0.35
CXCR4 P61073 1/20 0.34
PARP1 P09874 1/20 0.34
HRH4 Q9H3N8 1/20 0.31
CRHR1 P34998 1/20 0.31
CHRNB2 P17787 1/20 0.31
CHRNB4 P30926 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
GRIN2D O15399 1/20 0.31
GRIN3B O60391 1/20 0.31
GRIN1 Q05586 1/20 0.31
GRIN2A Q12879 1/20 0.31
GRIN2B Q13224 1/20 0.31
GRIN2C Q14957 1/20 0.31
GRIN3A Q8TCU5 1/20 0.31
DHFR P00374 1/20 0.30
HEXA P06865 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15318642 0.82 TSHR (0.35) NOS1NOS2KCNH2CXCR4PARP1
SCHEMBL21024617 0.81 KCNH2 (0.35) NOS1NOS2KCNH2GRIN1GRIN2B
SCHEMBL1581851 0.81 KCNH2 (0.36) NOS1NOS2KCNH2CXCR4PARP1
SCHEMBL31481285 0.81 KCNH2 (0.36) NOS1NOS2KCNH2CXCR4PARP1
SCHEMBL12299266 0.81 CCR1 (0.44) NOS1NOS2CRHR1GRIN2B
SCHEMBL23343749 0.79 ADORA2A (0.37) NOS1NOS2KCNH2CXCR4PARP1
SCHEMBL28518014 0.79 KCNH2 (0.39) NOS1NOS2KCNH2CXCR4PARP1
Ammonia Solution, Strong SCHEMBL7989286 0.79 KCNH2 (0.35) NOS1NOS2KCNH2CXCR4PARP1
SCHEMBL9876950 0.78 CCR1 (0.41) NOS1NOS2
SCHEMBL22895136 0.78 KCNH2 (0.34) NOS1NOS2KCNH2CXCR4PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230030414-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2023-02-02 US disclosed
EP-4059932-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE Vertex Pharmaceuticals Incorporated (US) 2022-09-21 EP disclosed
US-10961232-B2 Substituted pyrazines as ATR kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-03-30 US disclosed
US-10479784-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase VERTEX PHARMACEUTICALS INCORPORATED (US) 2019-11-19 US disclosed
US-20190047995-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2019-02-14 US disclosed
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE VERTEX PHARMACEUTICALS INCORPORATED 2018-06-21 US disclosed
US-9701674-B2 Substituted pyrazines as ATR kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2017-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10961232-B2 Substituted pyrazines as ATR kinase inhibitors ATR, MAP3K5, CHEK1 NOS1 3094/4885NOS2 3077/4885KCNH2 2661/4885
US-20190047995-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 NOS1 3172/4885NOS2 3048/4885KCNH2 2838/4885
US-20230030414-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 NOS1 3172/4885NOS2 3048/4885KCNH2 2838/4885
US-10479784-B2 Substituted pyrazin-2-amines as inhibitors of ATR kinase ATR, CHEK2, CHEK1 NOS1 2869/4885NOS2 2574/4885KCNH2 2280/4885
US-20180170922-A1 COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE ATR, CHEK1, MAP3K5 NOS1 3172/4885NOS2 3048/4885KCNH2 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.